This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

PepsiCo’s selloff presents the highest dividend yield in history. Find out why PEP stock might mirror the Dotcom bust ...

Brinker International’s turnaround drives growth, but 2H 2025 may see slower gains. Learn why EAT stock's fair value makes it ...

McKesson Corporation MCK reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of $8.03, which missed the ...

Cencora, Inc. COR reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of $3.73, which beat the Zacks Consensus Estimate of $3.50 by 6.6%. The bottom line also improved 13.7% year over ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Q3 2024 results showed net income of $45.9 million, up 71% year-over-year, along with EBITDA of $119.1 million, up 55% year-over-year. Gross profit also rose to $286 million. GLP increased its ...

Holders of Bachelors degree will normally be expected to have achieved a GPA of 3.0/4, 3.75/5 or 75% for 2:1 equivalency or 2.8/4, 3.5/5 or 70% for 2:2 equivalency. To reward outstanding achievement ...

DeepSeek released its buzziest large language model, R1, on Jan. 20. The AI assistant hit No. 1 on the Apple App Store in recent days, bumping OpenAI’s long-dominant ChatGPT down to No. 2.